Side Effects and Contraindications of Erythropoiesis-Stimulating Agents

ESAs should not be used in patients with known hypersensitivity to ESAs or their excipients, and are absolutely contraindicated in patients with poorly controlled hypertension 1.

Absolute Contraindications

Known hypersensitivity to ESAs or any excipients 1
Poorly controlled hypertension 1

Relative Contraindications and Cautions

ESAs should be used with extreme caution or avoided in:

Patients treated with curative intent (cancer cure as goal) 1, 2 - The FDA has indicated ESAs should not be given when the goal is to cure cancer 3
Cancer patients not receiving chemotherapy - there is an increased risk of death when ESAs are administered to target Hb of 12-14 g/dL 1, 2
Patients with impaired liver function - effects are unknown; use with caution 1
Predisposition to thromboses of arterio-venous fistulae 4
Thrombocytosis 4
History of convulsions 4

Major Side Effects and Safety Concerns

Cardiovascular and Thromboembolic Events

The most serious concern with ESAs is increased thromboembolic risk. The relative risk for thromboembolic events is increased by 67% in patients receiving ESAs 1. More specifically:

Thrombotic events increased by 69% (RR 1.69,95% CI 1.27 to 2.24) 5
Increased risk of stroke (suggested in studies) 6
Vascular thrombosis 6
Increased cardiovascular events 3, 5

Mortality Risk

ESAs increase all-cause mortality when used inappropriately. Key findings include:

15% increased mortality during treatment (RR 1.15,95% CI 1.03 to 1.29) in cancer patients 5
Increased mortality when targeting Hb >12 g/dL 1, 2
Shortened overall survival in some cancer patients 3
No mortality benefit in patients with heart disease; strong recommendation against use in CHF/CHD 6

Hypertension

Hypertension is a common and significant side effect:

Epoetin beta probably increases hypertension (OR 2.17,95% CI 1.17 to 4.00) 7
Epoetin alfa, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta may increase hypertension (OR ~1.88-2.10) 7
Hypertension aggravation is one of the most frequent adverse effects 4

Tumor Progression

ESAs may accelerate tumor growth in cancer patients:

ESAs have been found to speed tumor growth in some cancer patients 3
Decreased survival times and poorer loco-regional control or progression-free survival in studies targeting Hb >12 g/dL 1

Iron Deficiency

Development of iron deficiency is the most frequent adverse effect alongside hypertension 4
Functional iron deficiency can develop during ESA treatment, requiring monitoring and supplementation 8

Other Serious Adverse Events

16% increased risk of serious adverse events overall (RR 1.16,95% CI 1.08 to 1.25) 5
Increased risk when Hb exceeds target levels 1, 2

Critical Safety Parameters

Hemoglobin Targets and Monitoring

Never exceed Hb of 12 g/dL - this is a critical safety threshold 1, 2:

Reduce dose by 25-50% if Hb rises >2 g/dL per 4 weeks or exceeds 12 g/dL 1, 2
Discontinue therapy if Hb exceeds 13 g/dL until it falls below 12 g/dL, then restart at 25% lower dose 1, 2
Target Hb should be the lowest concentration needed to avoid transfusions 8

Monitoring Requirements

Baseline and periodic monitoring should include 8:

Iron studies (iron, total iron-binding capacity, transferrin saturation, ferritin)
Hemoglobin levels
Blood pressure monitoring (given hypertension risk)

Common Pitfalls to Avoid

Never use ESAs in cancer patients not receiving chemotherapy - this significantly increases mortality risk 1, 2
Never target Hb >12 g/dL - this increases cardiovascular events and mortality 1, 2
Don't continue beyond 6-8 weeks without response (defined as <1-2 g/dL Hb increase) - this provides no benefit 8, 1, 2
Don't use in patients with curative cancer treatment intent without extreme caution 1, 2
Don't ignore uncontrolled hypertension - this is an absolute contraindication 1

Patient Counseling Requirements

Healthcare providers must discuss 3:

ESAs shorten survival and speed tumor growth in some cancer patients
Increased risk of blood clots (thromboembolism)
Not recommended for cancer patients not receiving chemotherapy
Goal is to reduce transfusions, not normalize hemoglobin

What are the side effects and contraindications of erythropoiesis‑stimulating agents used to treat anemia?

Have a follow-up question?